Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production
Telmisartan depletes tumor PD-L1 but has significant PD-L1-independent clinical translational potential to improve PARPi in BRCA wild-type (WT) tumors and augment tumor immunogenicity.
Authors
- Akshaya Balasubramanian
- Bernice Leung (ORCID: https://orcid.org/0009-0008-0511-7212)
- Paige Blinkiewicz
- Nathaniel Spicer (ORCID: https://orcid.org/0000-0002-9106-1049)
- Eloïse Dray (ORCID: https://orcid.org/0000-0001-6793-9838)
- Anja Holtz (ORCID: https://orcid.org/0000-0001-9856-002X)
- W T Li
- Tyler Jay Curiel (ORCID: https://orcid.org/0000-0001-6962-9411)
- Chris Tanner
- Jordan Wentworth
- Weixing Zhao
- Haiyan Bai
- Clare E Murray
- Carlos O Ontiveros
Institutions
- Dartmouth College (US)
- The University of Texas at San Antonio Health Science Center (US)
- Dartmouth Psychiatric Research Center (US)
- Dartmouth Health (US)
- The University of Texas at San Antonio (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1136/jitc-2025-012426
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00